JFL Life Sciences Ltd

JFL Life Sciences Ltd, a micro-cap player in the Pharmaceuticals & Biotechnology sector, surged to hit its upper circuit price limit on 18 Mar 2026, registering a maximum daily gain of 4.66%. This sharp price movement was driven by robust buying interest, resulting in a regulatory freeze on further trading and highlighting significant unfilled demand in the stock.

JFL Life Sciences Ltd, a micro-cap player in the Pharmaceuticals & Biotechnology sector, witnessed a sharp decline on 16 Mar 2026, hitting its lower circuit price limit of ₹9.75. The stock recorded a maximum daily loss of 4.88%, underperforming its sector by 3.51% and reflecting intense selling pressure and panic among investors.

JFL Life Sciences Ltd is rated 'Sell' by MarketsMOJO, with this rating last updated on 29 January 2026. However, the analysis and financial metrics discussed here reflect the stock's current position as of 16 March 2026, providing investors with an up-to-date perspective on the company’s fundamentals, valuation, financial trends, and technical outlook.

Shares of JFL Life Sciences Ltd, a micro-cap player in the Pharmaceuticals & Biotechnology sector, plunged to their lower circuit limit on 13 Mar 2026, closing at ₹10.25, down 4.65% on the day. The stock’s sharp decline reflects intense selling pressure and panic among investors, with volumes and turnover indicating a significant imbalance between supply and demand.

JFL Life Sciences Ltd is rated 'Sell' by MarketsMOJO, with this rating last updated on 29 January 2026. However, the analysis and financial metrics presented here reflect the stock's current position as of 05 March 2026, providing investors with the latest insights into the company’s performance and outlook.

Shares of JFL Life Sciences Ltd plunged to their lower circuit limit on 5 Mar 2026, closing at ₹10.45, marking a maximum daily loss of 4.57%. The stock’s sharp decline reflects intense selling pressure and panic among investors, with volumes remaining subdued and supply largely unfilled, signalling a challenging outlook for this micro-cap pharmaceutical player.

Shares of JFL Life Sciences Ltd plunged to their lower circuit limit on 20 Feb 2026, closing at ₹10.40, marking a maximum daily loss of 4.59%. The micro-cap pharmaceutical stock faced intense selling pressure, with volumes rising amid panic selling and unfilled supply, signalling deep investor concerns despite the sector’s modest gains.

JFL Life Sciences Ltd is rated 'Sell' by MarketsMOJO, with this rating last updated on 29 January 2026. However, the analysis and financial metrics discussed here reflect the stock’s current position as of 18 February 2026, providing investors with an up-to-date perspective on the company’s performance and outlook.

JFL Life Sciences Ltd, a micro-cap player in the Pharmaceuticals & Biotechnology sector, surged to hit its upper circuit limit on 9 Feb 2026, registering a maximum daily gain of 4.57%. This sharp price movement was driven by robust buying interest, resulting in a regulatory freeze on further trading and signalling strong unfilled demand for the stock.

JFL Life Sciences Ltd is rated 'Sell' by MarketsMOJO, with this rating last updated on 29 January 2026. However, the analysis and financial metrics discussed here reflect the stock's current position as of 05 February 2026, providing investors with an up-to-date view of the company’s standing in the market.

Shares of JFL Life Sciences Ltd plunged to their lower circuit limit on 4 Feb 2026, closing at ₹10.55, down 3.65% from the previous close. The stock witnessed intense selling pressure, with volumes falling sharply and investor participation dwindling, signalling a wave of panic selling in this micro-cap pharmaceutical player.

Shares of JFL Life Sciences Ltd plunged to their lower circuit limit on 2 Feb 2026, closing at ₹10.45, marking a maximum daily loss of 5.0%. The stock faced intense selling pressure, with panic selling dominating trade and leaving significant unfilled supply at the close. This sharp decline comes amid deteriorating investor sentiment and a weak sectoral backdrop.

JFL Life Sciences Ltd surged to hit its upper circuit price limit on 30 Jan 2026, registering a maximum daily gain of 4.78% amid robust buying interest and heightened investor participation. The stock closed at ₹10.95, marking a notable outperformance against its sector and the broader market indices.

JFL Life Sciences Ltd has demonstrated a marked turnaround in its financial performance for the quarter ended December 2025, posting robust revenue growth and margin expansion that contrasts sharply with its recent historical trends. Despite persistent headwinds in the broader market and a challenging sector environment, the pharmaceutical and biotechnology company has improved its financial trend from flat to positive, signalling potential stabilisation and renewed investor interest.

JFL Life Sciences Ltd., a micro-cap pharmaceutical manufacturer with a market capitalisation of ₹33.00 crores, posted net profit of ₹1.97 crores in Q2 FY26, marking a sequential surge of 162.67% quarter-on-quarter but declining 35.86% year-on-year. The stock, trading at ₹10.45 as of January 29, 2026, gained 4.50% in the latest session but remains under severe pressure, having plunged 53.96% over the past year and trading near its 52-week low of ₹10.00.

JFL Life Sciences Ltd is rated 'Sell' by MarketsMOJO, with this rating last updated on 26 August 2025. However, the analysis and financial metrics discussed here reflect the stock's current position as of 22 January 2026, providing investors with an up-to-date perspective on the company’s performance and outlook.